Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study.
Cordone I, Marchesi F, Masi S, Summa V, Pisani F, Merola R, Cigliana G, Orlandi G, Gumenyuk S, Palombi F, Romano A, Spadea A, Renzi D, Papa E, Canfora M, Conti L, Petti MC, Mengarelli A. Cordone I, et al. Among authors: summa v. J Exp Clin Cancer Res. 2016 Mar 19;35:49. doi: 10.1186/s13046-016-0324-0. J Exp Clin Cancer Res. 2016. PMID: 26992692 Free PMC article.
Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study.
Torti C, Olimpieri PP, Bonfanti P, Tascini C, Celant S, Tacconi D, Nicastri E, Tacconelli E, Cacopardo B, Perrella A, Buccoliero GB, Parruti G, Bassetti M, Biagetti C, Giacometti A, Erne EM, Frontuto M, Lanzafame M, Summa V, Spagnoli A, Vestri A, Di Perri G, Russo P, Palù G. Torti C, et al. Among authors: summa v. Lancet Reg Health Eur. 2023 Jul 14;31:100684. doi: 10.1016/j.lanepe.2023.100684. eCollection 2023 Aug. Lancet Reg Health Eur. 2023. PMID: 37547273 Free PMC article.
Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA).
Breccia M, Olimpieri PP, Celant S, Olimpieri OM, Pane F, Iurlo A, Summa V, Corradini P, Russo P. Breccia M, et al. Among authors: summa v. Ann Hematol. 2023 May;102(5):1257-1259. doi: 10.1007/s00277-023-05168-8. Epub 2023 Mar 13. Ann Hematol. 2023. PMID: 36914888 No abstract available.
Flow cytometry characterization in central nervous system and pleural effusion multiple myeloma infiltration: an Italian national cancer institute experience.
Marchesi F, Masi S, Summa V, Gumenyuk S, Merola R, Orlandi G, Cigliana G, Palombi F, Pisani F, Romano A, Spadea A, Papa E, Canfora M, De Bellis F, Conti L, Mengarelli A, Cordone I. Marchesi F, et al. Among authors: summa v. Br J Haematol. 2016 Mar;172(6):980-2. doi: 10.1111/bjh.13549. Epub 2015 Jun 17. Br J Haematol. 2016. PMID: 26081466 Free article. No abstract available.
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency.
Rigolin GM, Olimpieri PP, Summa V, Celant S, Scarfò L, Tognolo L, Ballardini MP, Urso A, Sessa M, Gambara S, Cura F, Fortini M, Ghia P, Cuneo A, Russo P. Rigolin GM, et al. Among authors: summa v. Blood Cancer J. 2023 Jun 28;13(1):99. doi: 10.1038/s41408-023-00865-z. Blood Cancer J. 2023. PMID: 37380630 Free PMC article.
How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA).
Breccia M, Olimpieri PP, Olimpieri O, Pane F, Iurlo A, Foggi P, Cirilli A, Colatrella A, Cuomo M, Gozzo L, Summa V, Corradini P, Russo P; AIFA’s Monitoring Registries Group. Breccia M, et al. Among authors: summa v. Cancer Med. 2020 Jun;9(12):4160-4165. doi: 10.1002/cam4.3071. Epub 2020 Apr 22. Cancer Med. 2020. PMID: 32319737 Free PMC article.
Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA).
Breccia M, Celant S, Olimpieri PP, Olimpieri OM, Pane F, Iurlo A, Cirilli A, Colatrella A, Gozzo L, Pugliese S, Summa V, Foggi P, Corradini P, Russo P; AIFA Monitoring Registries Group. Breccia M, et al. Among authors: summa v. Ann Hematol. 2021 Feb;100(2):481-485. doi: 10.1007/s00277-021-04406-1. Epub 2021 Jan 7. Ann Hematol. 2021. PMID: 33415425
134 results